Enterprise Applauds iPrEx Study Partners and Volunteers – Study adds to Most Promising Period in HIV Prevention Research Since Epidemic Began

The Global HIV Vaccine Enterprise released a statement today on the announcement of the results of the first study of oral pre-exposure prophylaxis (PrEP) for HIV prevention in humans.  "The iPrEx study, is a very important addition to what is the most promising 15 months in the field of HIV prevention research since the epidemic began 27 years ago."  The full statement is available below.

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account